Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial

Kezar Life Sciences, Inc.

2025-Q2 EPS reported -$4.14 vs consensus -$2.41 ▼ miss (-71.6%)

Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.
Cash, equivalents & marketable securities $100.8M as of June 30, 2025 ($132.2M at Dec 31, 2024).
FDA removed partial clinical hold on PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis.
Submitted Type C meeting request to FDA for Q4 2025 to discuss registration-enabling AIH study design.
PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025 (Nov 7-11).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.